HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning.

Abstract
To determine if pulmonary perfusion was improved in acute pulmonary embolism after therapy with recombinant human tissue-type plasminogen activator (rt-PA), lung scans were obtained before and a mean of 22 hours after therapy in 19 patients. The posttherapy lung scans were compared with baseline, pretherapy scans with use of two semiquantitative methods--an anteroposterior view method, similar to that used in the Urokinase Pulmonary Embolism Trial, and a segmental method that emphasized pulmonary anatomy. There was an improvement in the defect score from 0.35 to 0.14 (P less than .01) when the anteroposterior view method was used and from 0.37 to 0.16 (P less than .01) when the segmental method was used. These encouraging results in the early posttherapy period suggest that rt-PA is especially effective in improving regional perfusion after pulmonary embolism and that a larger controlled trial of therapy with rt-PA for acute pulmonary embolism should be performed. Scoring lung scans with a segmental method is feasible and appropriate for present-day lung scan technique and should be considered in future studies.
AuthorsJ A Parker, J E Markis, A Palla, S Z Goldhaber, H D Royal, S Tumeh, D Kim, A K Rustgi, B L Holman, G M Kolodny
JournalRadiology (Radiology) Vol. 166 Issue 2 Pg. 441-5 (Feb 1988) ISSN: 0033-8419 [Print] UNITED STATES
PMID3122266 (Publication Type: Journal Article)
Chemical References
  • Recombinant Proteins
  • Technetium Tc 99m Aggregated Albumin
  • Tissue Plasminogen Activator
Topics
  • Adult
  • Aged
  • Female
  • Humans
  • Lung (radionuclide imaging)
  • Male
  • Middle Aged
  • Pulmonary Circulation
  • Pulmonary Embolism (drug therapy, radionuclide imaging)
  • Recombinant Proteins (therapeutic use)
  • Technetium Tc 99m Aggregated Albumin
  • Tissue Plasminogen Activator (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: